Clinical Value Of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography In Patients With Renal Diseases Ocr

28 Objectives: The incidence of cancer in patients with renal disease is significantly higher than that in normal population. It is necessary to identify whether the kidney damage is secondary to the tumor or associated with the tumor. This study is to evaluate the value of 18F-FDG PET/CT in patients with renal disease. Methods: We reviewed 146 18F-FDG PET/CT subjects diagnosed with renal diseases from January 2014 to December 2017. Results were analyzed by qualitative and semi-quantitative methods based on pathological findings and clinical follow-up (greater than 3 months). Statistical analysis was performed using the intergroup t test. Results: 146 patients with renal diseases included 74 cases of primary nephropathy and 72 cases of secondary nephropathy. A total of 72 patients were found with abnormal FDG uptake (49.3%). Suspected tumors were found in 34 cases and 29 cases (19.9%) were finally diagnosed with tumors. 18F-FDG PET/CT had the sensitivity of 100% and accuracy of 85.3%. The SUVmax of tumor lesion was 6.4 ± 5.1 (n = 29). In 19 patients with secondary nephropathy by tumor, SUVmax was 6.0±3.0 (n=19). There were 10 cases of nephropathy coincident with tumors, with SUVmax of 6.0±3.0 (n=10). There was no significant difference in SUVmax between the secondary and concomitant tumor groups (P > 0.05). The FDG uptake in tumors involving the kidney was significantly higher than that in primary renal impact lesions (P < 0.05). Conclusions: 18F-FDG PET/CT can be used to exclude and screen suspected tumors and infection in the whole body for patients with renal diseases.